With drug delivery systems becoming central to improving therapeutic outcomes and patient experience, advancements in capsule technology are paving the way for more precise and efficient formulations.
This was the focus of the session titled ‘Drug Delivery Systems – Advances in Capsule Technology’ at the FDD Conclave 2025. Conducted by Lekhna Ajgaonkar Kumar, Associate Director – Marketing at Lonza Capsules & Health Ingredients, the session showcased how the company’s capsule innovations are helping pharmac partners overcome longstanding formulation challenges while streamlining the path from development to commercialisation.
The session highlighted Lonza’s evolution into a preferred partner for pharma companies globally, offering end-to-end support that spans preclinical research, clinical trials, production, logistics, regulatory guidance, and compliance. This holistic involvement across functions allows Lonza to offer not just products, but integrated solutions tailored to the complex needs of modern drug development.
At the heart of the presentation was Capsugel Enprotect, Lonza’s innovative capsule technology designed to address the limitations of traditional enteric-coated systems. Unlike conventional methods that require additional coating steps, Enprotect capsules inherently protect acid-sensitive ingredients from stomach degradation and enable targeted intestinal release.
This advancement simplifies manufacturing, enhances reproducibility, and reduces formulation complexity— making it a compelling option for formulators working with challenging APIs. In addition to its technical merits, Ajgaonkar Kumar also framed capsule innovation as an enabler of patientcentric drug delivery.
She also pointed out that by improving stability, bioavailability, and dosing precision, capsule technologies like Enprotect contribute to better adherence and therapeutic success, particularly for sensitive or specialty drugs.
The session underscored how the company’s formulation technologies are shaping the future of oral drug delivery and reaffirmed its commitment to supporting pharma innovation across every stage of development.